Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

SUMATRIPTAN SUCCINA

Open
SPE2DP-26-T-1433Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

325411 - Medicinal and Botanical Manufacturing

Place of Performance

BLDG 4 D STREET, WILLIAMSBURG, VA, 23185, USA

Set-Aside

NONE

Documents

1
PDF

Read the document

Due in 5 days

Every page of every file, in your free workspace.

Read the document

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Due in 5 days

Everything you need to bid on this one

Open the full contract in your free workspace.

  • 1 solicitation documentRead every page
  • Buyer contactEmail and phone
Open the full contract

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Contacts1 person available
OfficeUSA

Full Description

Show more
SUMATRIPTAN SUCCINA
SUMATRIPTAN SUCCINA
SUMATRIPTAN SUCCINATE TABLETS, 100MG BOTTLE OF 9 TABLETS. STORE AT 20
TO 25 C (68 TO 77 F). [SEE USP CONTROLLED ROOM TEMPERATURE.]PROTECT
FROM LIGHT. INDICATED FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR
WITHOUT AURA IN ADULTS.
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
RD003, COVERED DEFENSE INFORMATION MAY APPLY
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description.
RS016: Shelf-life requirement RS001 for a TYPE I (CODE M) item with a shelf life of 24 months (non-extendable) applies to this item.
Shall be marked IAW the latest edition of Medical Marking Standard No. 1 https://www.dla.mil/Logistics-Operations/Packaging/
MYLAN PHARMACEUTICALS INC 3KJG9 P/N NDC00378-5632-59 GOLDEN STATE MEDICAL SUPPLY, INC. 1HT23 P/N NDC51407-0013-09
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://www.dla.mil/Portals/104/Documents/DLMS/eApplications/LogDataAdmin/ UnitofIssueandPurchaseUnit.xlsx
SPE2DP-26-T-1433
SECTION B
PR: 7015262257 PRLI: 0001 CONT’D
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7015262257 0001 BT 58.000
NSN/MATERIAL:6505017278704
DELIVERY (IN DAYS):0020
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
QUP:001 PRES MTHD:ZZ CLNG/DRY:Z PRESV MAT:ZZ
WRAP MAT:ZZ CUSH/DUNN MAT:ZZ CUSH/DUNN THKNESS:Z
UNIT CONT:ZZ OPI:M
INTRMDTE CONT:ZZ INTRMDTE CONT QTY:ZZZ
PACK CODE:U
MARKING SHALL BE IN ACCORDANCE WITH MIL-STD-129.
SPECIAL MARKING CODE:ZZ -ZZ Special Requirements
PALLETIZATION SHALL BE IN ACCORDANCE WITH RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RS016: Shelf-life requirement RS001 for a TYPE I (CODE M) item with a shelf life of 24 months (non-extendable) applies to this item.
Shall be marked IAW the latest edition of Medical Marking Standard No. 1 https://www.dla.mil/Logistics-Operations/Packaging/
PARCEL POST ADDRESS:
V4582F
NAVY EXPEDITIONARY CENTRAL FACILITY
CENTRAL ISSUE FACILITY
BLDG 4 D STREET
WILLIAMSBURG VA 23185
US
VESSEL SHIPMENT. TRANSPORTATION SEE DLAD PROC NOTE C19. FIRST DESTINATION TRANSPORTATION SEE DLAD PROC
NOTE C20 AND CONTRACT
FREIGHT SHIPPING ADDRESS:
V4582F
NAVY EXPEDITIONARY CENTRAL FACILITY
CENTRAL ISSUE FACILITY
BLDG 4 D STREET
WILLIAMSBURG VA 23185
US
SHIP BY FASTEST TRACEABLE MEANS. DO NOT USE PARCEL POST.
M/F: (TCN) V4582F6021M096
RDD:
SPE2DP-26-T-1433
SECTION B
PR: 7015262257 PRLI: 0001 CONT’D
PROJ: LP5 TP 2
SUPP ADD: SIG: A
FOR GOVERNMENT USE ONLY: (IPD) 06
DIC: A4A DIST: 9B ADV: 2A FC: P7
Need Ship Date:00/00/0000 Original Required Delivery Date:01/28/2026
SPE2DP-26-T-1433 NSN/Part Number: 6505-01-727-8704 Quantity: 58 BT Purchase Request: 7015262257QTY: 58 Delivery: 20 days ADO

Similar Contracts

Same NAICS industry code

NAICS: 325411
New
Federal
Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics
Solicitation # 75N98027R00020
The National Center for Advancing Translational Sciences within the National Institutes of Health has issued a Sources Sought notice for an IDIQ contract focused on reagent generation for bioanalytical method development on biologics therapeutics. The primary objective is to identify qualified sources capable of generating and delivering high-affinity, specific anti-drug antibodies, including neutralizing antibodies and antibodies against carriers or gene-of-interest protein products. These reagents will support the quantification of novel biologic drugs in biological matrices such as plasma, serum, and tissue homogenates. The anticipated scope includes the production of polyclonal and monoclonal antibodies, specificity characterization, and the delivery of purified antibodies at an estimated scale of 10 to 50 mg per reagent. The required performance standards are rigorous, demanding adherence to US FDA current Good Manufacturing Practice, Good Laboratory Practice, and Good Clinical Practice, as well as ICH and ISO regulations. Contractors must maintain a comprehensive Quality Management Plan and an independent Quality Assurance Unit to ensure all products meet strict quality requirements. Additional requirements include the development of standard operating procedures for packaging and shipping, the maintenance of secure facilities with restricted access, and the implementation of contingency plans for catastrophic events. The anticipated period of performance for this effort is ten years. Interested respondents must be registered in the System for Award Management and provide a capability statement under NAICS code 325411 by November 30, 2026.
National Institutes Of Health Nida

POSTED

4 days ago

DEADLINE

in 10 days
View Details

More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

Same awarding agency

Get AI-powered intelligence on this solicitation and the ones like it

Every solicitation package arrives shredded into a compliance breakdown and matched to your past performance, with incumbent history and alerts on amendments and award.

Miguel
Hillary
Keith Deutsch
Christine

Join 900+ contractors already using CLEATUS